-

GQC Is Born: the First Start-up, Federated by PQE Group, to Support Medical Cannabis

PARMA, Italy--(BUSINESS WIRE)--The world's first start-up to support pharmaceutical companies in every aspect of medical cannabis development and distribution is Italian. Named GQC - Glocal Quality Cannabis, it is one of the federated companies of PQE Group, an international life sciences consulting giant that, for almost 25 years, has been supporting major companies in all phases of the drug life cycle, from molecule creation to distribution.
Engineering, GxP quality compliance, regulatory affairs, medical-scientific advisory, clinical studies and a GQC academy: these are the primary services that GQC will make available to clients through the significant knowledge gained by PQE Group over more than two decades.

"This new project represents an important challenge for me. I strongly believe in the therapeutic power of cannabis in the medical world,’ said Gilda D'Incerti, PQE Group CEO & Founder and President of GQC. “I wanted to support the field of research as well as the development and dissemination of medical cannabis through the creation of this new start-up. I personally, and with great care, researched the professionals who make up the new GQC team: chemists, pharmacists, physicians, and biologists who take care of the supply chain at three hundred and sixty degrees."

However, the market still struggles with fragmented and sometimes obscure national legislation. This is precisely where GQC's innovative proposal fits in, which will apply the highest international standards locally to always guarantee efficacy, safety, and quality to the end patient.

"I believe that medical cannabis should be treated the same as any other pharmaceutical product. Our vision is to support the development of new therapies through effective management of data quality by accelerating the registration of cannabis products and reducing the timing of the supply chain to be faster for the patients,” Riccardo Salvagnini, GQC VP Executive, said during the start-up's launch ceremony. “Therefore, we want to provide effective technological solutions to medical cannabis products to accelerate our go-to-market strategy through a local approach but with a global mindset. Our quality services support each process and technology to navigate regulations worldwide and provide access to medicines faster and more efficiently. Too often," Salvagnini concludes, "patients still have difficulty finding these drugs due to a lack of availability of the raw material, which undermines their right to access care."

Contacts

Press office: Laura Piccioli pressoffice@pqegroup.com

More News From PQE Group

PQE Group Joins Project-COMFORT to Advance Patient-Centric Blood Collection and Diagnostics

ROME--(BUSINESS WIRE)--PQE Group, a global consulting firm specializing in Life Sciences, is proud to contribute its expertise as a strategic partner in the Project-COMFORT consortium. This innovative public-private partnership, funded by Horizon Europe and supported by the Innovative Health Initiative Joint Undertaking (IHI JU), officially launched in November 2024, marking a transformative shift in blood collection and diagnostics. The ambitious 42-month project brings together 51 organizatio...

PQE Group Receives Certifications from ISO/IEC 27001 and A Women’s Business Enterprise

NEW YORK--(BUSINESS WIRE)--PQE Group is proud to announce its most recently-received official recognitions: ISO/IEC 27001 and A Women’s Business Enterprise (WBE) Certifications, which provide additional reasons to recognize PQE Group’s extensive capabilities; the ISO/IEC 27001 provides clients assurance that their information management systems are risk-aware and that PQE Group’s solutions can proactively identify and address weaknesses; the WBE Certification ensures that PQE Group has met the...

PQE Group Launches AI and Data Analytics Division: Innovation in the Service of Life Science

FLORENCE, Italy--(BUSINESS WIRE)--PQE Group, a leading consultancy in the Life Science sector, announces the consolidation of its new Regulated Artificial Intelligence & Data Analytics division operating since the initiation of AI based tools in the industrial space. This marks a pivotal step in the company's evolution, positioning the Italian Group, comprised of more than 2000 employees, at the forefront of technological innovation in Life Sciences. The new division is designed to enhance...
Back to Newsroom